Research
Hormonal
Discontinuation of second-generation OMMs leads to significant weight regain, highlighting the chronic nature of obesity and the need for long-term management or intensive lifestyle support upon discontinuation.
Stopping OMMs typically leads to significant weight regain. If you choose to discontinue, work with your healthcare provider to intensify lifestyle interventions, including dietary strategies and physical activity, to help maintain your weight loss.
StrongSupportsHIGH confidence
In the STEP 4 trial, after the semaglutide lead-in those who continued on semaglutide lost an additional − 7.9% while those on placebo gained + 6.9% [77].
Why this rating
Based on multiple randomized withdrawal trials (STEP 4, SURMOUNT-4).
Source
To Reenvision and Redefine: Considering the Role of Lifestyle Interventions in the New Era of Second-Generation Obesity Management Medications
Alexandra Peary et al. · Current Atherosclerosis Reports · 2026
DOI 10.1007/s11883-026-01426-y
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Second-generation obesity management medications (semaglutide and tirzepatide) produce 15-20% body weight loss, significantly exceeding the 5-10% typically achieved by lifestyle interventions alone.Strong
- Lifestyle interventions during OMM treatment should shift focus from caloric deficit for weight loss to optimizing health, specifically by mitigating lean mass loss through high protein intake and resistance training.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →